For U.S. Healthcare Professionals Only Sanofi Genzyme

The only microtubule inhibitor approved in combination with prednisone for treatment of patients with metastatic castration-resistant prostate cancer previously treated with a docetaxel-containing regimen.

NCCN and PCWG Recommend mCRPC Patients Be Monitored Closely for Progression1,2

  • NCCN recommends using PSA tests, radiologic imaging (CT, bone scan), and clinical exams to monitor closely for progression.
  • The prostate cancer trials working group (PCWG) has also published additional recommendations.
Monitoring recommendations/guidelines by NCCN for metastatic disease1   Indicators of disease progression according to PCWG32
PSA measurement every 3-6 months based on clinical judgement

Increased risk for bone metastasis or death with a PSADT of <8 months
  Rising PSA levels
Frequency of imaging should be based on individual risk, age, PSADT, Gleason score, and overall health.

i.e. bone scans* every 8-12 weeks
PSADT <8 months, perform bone imaging more frequently
  New lesions
History and physical examination every 3-6 months   Pain

PSADT=PSA doubling time

*Bone scans are useful to monitor mCRPC to determine the clinical benefit of systematic therapy. However, new lesions comparing pre and post-treatment bone scans may not indicate disease progression. New lesions in the setting of a falling PSA or soft tissue response and in the absence of pain progression at the site may indicate bone scan flare or an osteoblastic healing reaction.



  • Neutropenic deaths have been reported. Obtain frequent blood counts to monitor for neutropenia. JEVTANA is contraindicated in patients with neutrophil counts of ≤1,500 cells/mm3. Primary prophylaxis with G-CSF is recommended in patients with high-risk clinical features.
  • Severe hypersensitivity reactions can occur and may include generalized rash/erythema, hypotension and bronchospasm. Severe hypersensitivity reactions require immediate discontinuation of the JEVTANA infusion and administration of appropriate therapy. Patients should receive premedication. JEVTANA is contraindicated in patients who have a history of severe hypersensitivity reactions to cabazitaxel or to other drugs formulated with polysorbate 80.

You are about to leave

You are leaving to view another Sanofi Genzyme Corporation website.